US2004002466A1PendingUtilityA1

Targeted delivery of genes encoding interferon

Assignee: IMMUNE RESPONSE CORP INCPriority: Mar 14, 1996Filed: Nov 26, 2001Published: Jan 1, 2004
Est. expiryMar 14, 2016(expired)· nominal 20-yr term from priority
A61K 48/0066C12N 15/87A61K 47/645A61K 38/212A61P 43/00A61K 48/0058A61K 48/00
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A molecular complex comprising a gene encoding interferon releasably linked to a conjugate of a nucleic acid binding agent and a ligand which binds to a component on the surface of a cell. In a preferred embodiment, the gene encodes human IFN-α, IFN-β, or IFN-γ. The complex can be used to obtain targeted expression of interferon in selected cells either in vivo or in vitro.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of delivering a gene encoding interferon to a target cell in a mammal, resulting in expression of the gene as a protein and secretion of the protein by the cell, the method comprising administering to the mammal a molecular complex comprising a gene encoding interferon releasably linked to a conjugate of a nucleic acid binding agent and a ligand which binds to a component on the surface of the target cell, wherein the gene is operably linked to genetic regulatory elements necessary for expression, processing and secretion of the encoded protein by the target cell.  
     
     
         2 . The method of  claim 1  wherein the gene encodes human interferon.  
     
     
         3 . The method of  claim 1  wherein the human interferon is IFN-α.  
     
     
         4 . The method of  claim 1  wherein the gene encodes human IFN-α2b.  
     
     
         5 . The method of  claim 1  wherein the gene is contained in an expression vector.  
     
     
         6 . The method of  claim 1  wherein the nucleic acid binding agent is a polycation.  
     
     
         7 . The method of  claim 6  wherein the polycation is polylysine.  
     
     
         8 . The method of  claim 1  wherein the ligand comprises a terminal carbohydrate residue.  
     
     
         9 . The method of  claim 1  wherein the ligand binds to the asialoglycoprotein receptor.  
     
     
         10 . The method of  claim 1  wherein the ligand is an asialoglycoprotein.  
     
     
         11 . The method of  claim 1  wherein the ligand is selected from the group consisting of galactose, mannose and lactose.  
     
     
         12 . The method of  claim 1  wherein the molecular complex is administered intravenously.  
     
     
         13 . A molecular complex comprising a gene encoding interferon releasably linked to a conjugate of a nucleic acid binding agent and a ligand which binds to a component on the surface of a cell, the gene being linked to genetic regulatory elements necessary for expression, processing and secretion of the encoded product by the cell.  
     
     
         14 . The molecular complex of  claim 13  wherein the gene encodes human interferon.  
     
     
         15 . The molecular complex of  claim 13  wherein the human interferon is IFN-α.  
     
     
         16 . The molecular complex of  claim 13  wherein the gene encodes human IFN-α2b.  
     
     
         17 . The molecular complex of  claim 13  wherein the gene is contained in an expression vector.  
     
     
         18 . The molecular complex of  claim 13  wherein the nucleic acid binding agent is a polycation.  
     
     
         19 . The molecular complex of  claim 18  wherein the polycation is polylysine.  
     
     
         20 . The molecular complex of  claim 13  wherein the ligand comprises a terminal carbohydrate residue.  
     
     
         21 . The molecular complex of  claim 13  wherein the ligand binds to the asialoglycoprotein receptor.  
     
     
         22 . The molecular complex of  claim 13  wherein the ligand is an asialoglycoprotein.  
     
     
         23 . The molecular complex of  claim 13  wherein the ligand is selected from the group consisting of galactose, mannose and lactose.  
     
     
         24 . A composition comprising the molecular complex of  claim 13  and a pharmaceutically acceptable carrier.  
     
     
         25 . A method of recombinantly expressing interferon in culture comprising incubating a host cell with a molecular complex comprising a gene encoding interferon releasably linked to a conjugate of a nucleic acid binding agent and a ligand which binds to a component on the surface of the host cell, the gene being linked to genetic regulatory elements necessary for expression, processing and secretion of the encoded interferon protein by the host cell.  
     
     
         26 . The method of  claim 25  wherein the gene encodes human IFN-α.  
     
     
         28 . The method of  claim 25  wherein the conjugate comprises a polycation linked to a ligand for the asialoglycoprotein receptor.  
     
     
         29 . A method for treating hepatitis infection in a patient comprising administering to the patient a molecular complex comprising a gene encoding human interferon-α releasably linked to a conjugate of a polycation and a ligand which binds to the asialoglycoprotein receptor present on the surface of liver cells, the gene being in a form suitable for expression, processing and secretion of the encoded product by the liver cells.  
     
     
         30 . The method of  claim 29  wherein the gene encodes human IFN-α2b.

Join the waitlist — get patent alerts

Track US2004002466A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.